• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Carmell Corporation

    1/29/25 3:20:24 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care
    Get the next $CTCX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001842939
    Carmell Therapeutics Corp
    ALPHA HEALTHCARE ACQUISITION CORP III
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Carmell Corp
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
       Over Five Years Ago
    X Within Last Five Years (Specify Year) 2021
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Carmell Corp
    Street Address 1 Street Address 2
    2403 SIDNEY STREET SUITE 300
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    PITTSBURGH PENNSYLVANIA 15203 412-894-8248

    3. Related Persons

    Last Name First Name Middle Name
    Shukla Rajiv
    Street Address 1 Street Address 2
    2403 Sidney Street Suite 300
    City State/Province/Country ZIP/PostalCode
    Pittsburgh PENNSYLVANIA 15203
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Frisch Scott
    Street Address 1 Street Address 2
    2403 Sidney Street Suite 300
    City State/Province/Country ZIP/PostalCode
    Pittsburgh PENNSYLVANIA 15203
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cassaday Bryan
    Street Address 1 Street Address 2
    2403 Sidney Street Suite 300
    City State/Province/Country ZIP/PostalCode
    Pittsburgh PENNSYLVANIA 15203
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Gregory Kathryn
    Street Address 1 Street Address 2
    2403 Sidney Street Suite 300
    City State/Province/Country ZIP/PostalCode
    Pittsburgh PENNSYLVANIA 15203
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Spenlehauer Gilles S.
    Street Address 1 Street Address 2
    2403 Sidney Street Suite 300
    City State/Province/Country ZIP/PostalCode
    Pittsburgh PENNSYLVANIA 15203
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sturgeon Patrick
    Street Address 1 Street Address 2
    2403 Sidney Street Suite 300
    City State/Province/Country ZIP/PostalCode
    Pittsburgh PENNSYLVANIA 15203
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Upton Richard
    Street Address 1 Street Address 2
    2403 Sidney Street Suite 300
    City State/Province/Country ZIP/PostalCode
    Pittsburgh PENNSYLVANIA 15203
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
    X Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-01-16    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
    X Yes    No

    Clarification of Response (if Necessary):

    Shares of issuer's common stock were issued as partial consideration in the acquisition of substantially all assets of Elevai Skincare, Inc. (Seller) and PMGC Holdings Inc. (previously Elevai Labs Inc.) related to Seller's skincare/haircare business.

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $1,075,463 USD
    or    Indefinite
    Total Amount Sold $975,463 USD
    Total Remaining to be Sold $100,000 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    The Total Offering Amount is the aggregate dollar value of the stock consideration to be issued in the acquisition. $100,000 of shares of the issuer's common stock will be withheld for 12 months following closing as an indemnification holdback.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Carmell Corp /s/ Bryan Cassaday Bryan Cassaday Chief Financial Officer 2025-01-28

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $CTCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTCX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CTCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Upton Richard A bought $2,336 worth of shares (5,000 units at $0.47), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    9/16/24 4:30:07 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Director Frisch Scott M. bought $515 worth of shares (1,009 units at $0.51) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    9/10/24 4:30:11 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Director Gregory Kathryn bought $643 worth of shares (1,260 units at $0.51) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    9/10/24 4:30:16 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY

    Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX, CTCXW)), a bio-aesthetics company (the "Company", "we", "our", or "us"), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launc

    3/10/25 8:30:00 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Announces Closing of Elevai Skincare Acquisition

    PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of the previously announced acquisition of the skin and hair care business of Elevai Skincare, Inc. ("Elevai"), a leader in physician dispensed exosome skin and hair care products, pursuant to a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) ("PMGC") and Elevai, its wholly owned subsidiary (the "Acquisition"). At the closing of the Acquisition (the "Closing"), the purchase consideration consisted of the following: Approximately $1.1 mill

    1/16/25 8:00:28 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Announces Closing of Previously Announced PIPE Investment from Existing and New Investors to Support Commercial Build-out

    PITTSBURGH, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of its previously announced private placement with new and existing investors pursuant to a securities purchase agreement, dated December 23, 2024, for the issuance and sale of 8,065,210 shares of its common stock and an equal number of five-year warrants both priced at $0.23 per share, in a private placement for aggregate gross proceeds of $1.85 million before deducting offering expenses and fees (the "Private Placement"). The Private Placement was priced at a slight premium t

    1/3/25 8:00:03 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    SEC Filings

    View All

    SEC Form 424B3 filed by Carmell Corporation

    424B3 - Longevity Health Holdings, Inc. (0001842939) (Filer)

    3/26/25 5:01:17 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Longevity Health Holdings, Inc. (0001842939) (Filer)

    3/26/25 5:00:09 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Carmell Corporation

    424B3 - Longevity Health Holdings, Inc. (0001842939) (Filer)

    3/10/25 8:53:40 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Bracken-Ferguson Kendra

    4 - Carmell Corp (0001842939) (Issuer)

    11/8/24 5:13:51 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Gregory Kathryn

    4 - Carmell Corp (0001842939) (Issuer)

    11/8/24 5:00:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Cassaday Bryan J.

    4 - Carmell Corp (0001842939) (Issuer)

    11/8/24 5:00:12 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    12/6/24 4:16:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    11/14/24 2:48:40 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Carmell Corporation (Amendment)

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    4/18/24 3:03:07 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Leadership Updates

    Live Leadership Updates

    View All

    CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY

    Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX, CTCXW)), a bio-aesthetics company (the "Company", "we", "our", or "us"), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launc

    3/10/25 8:30:00 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index

    PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Company" or "Carmell"), today announced the appointment of Ms. Kendra Bracken-Ferguson as Chief Executive Officer effective July 30, 2024 with Mr. Rajiv Shukla continuing to serve as Executive Chairman of the Company. Kendra's appointment comes at a pivotal moment of growth for the Company. Since its business combination in July 2023, the Company has completed a pivot towards skincare, recruited a top-tier Scientific Advisory Board, developed and tested 12 skincare products aimed at retail and medspa use, scaled up in-house manufacturing and packagi

    7/29/24 8:30:00 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

    PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the execution of a definitive agreement to sell its wholly owned subsidiary, Axolotl Biologix ("AxoBio") to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million. "The sale of AxoBio enables our exit from the tissue graft space thereby facilitating a sharper organizational focus on the launch of our skincare products beginning in March 2024 and co

    3/20/24 4:39:36 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care